Instrument Inactif

Communiqués Akers Biosciences Inc Nasdaq

Actions

US00973E1029

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

MyMD Pharmaceuticals : Modification to Rights of Security Holders Form 8 K	24/06	PU
MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer	17/06	BU
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers	03/06	AQ
MyMD Pharmaceuticals : Modification to Rights of Security Holders - Form 8-K	23/05	PU
MyMD Pharmaceuticals : Secures Strategic Investments - Form 8-K	21/05	PU
MyMD Pharmaceuticals Secures Strategic Investments	21/05	BU
Ladenburg Thalmann, Esteemed Wall Street Long-Standing Stalwart Since 1876, Advocates 'Buy' for Intelligent Bio, Precision Bio, and More: VTAK, INBS, LASE, MYMD, RVSN	10/04	AQ
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing	05/03	BU
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing	13/02	BU
MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis	06/12	BU
Developing a first-in-class small molecule drug for inflammatory disease	09/11	AQ
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain	20/10/23	AQ
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain	19/10/23	BU
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF- Market Disrupter, at BioFuture 2023	05/10/23	AQ
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023	04/10/23	BU
FDA Accepts MyMD Pharmaceuticals Investigational New Drug Application for Phase 2 Study of oral TNF- inhibitor MYMD-1 in Rheumatoid Arthritis	15/08/23	AQ
FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)	14/08/23	BU
MyMD Pharmaceuticals : Joshua Silverman - Chairman, MyMD Pharmaceuticals, Inc. Chris Chapman - President, Director, and Chief Medical Officer, MyMD Pharmaceuticals, Inc. Adam Kaplin - Chief Scientific Officer, MyMD Pharmaceuticals, Inc - Form 8-K	03/08/23	PU
Top Under-the-Radar Small Cap Stocks to Watch Now! STPGF / STGO.T, WKHS, MYMD, KAVL, HNRC	03/08/23	AQ
MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results	02/08/23	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Akers Biosciences Inc Nasdaq

Actions

US00973E1029

Communiqués

Filtres